Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.79 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.77 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.77 |
| ▸ | PARP1 | P09874 | 5/20 | 0.77 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.77 |
| ▸ | PARP14 | Q460N5 | 4/20 | 0.77 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.72 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.72 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9364423 | 1.00 | CREBBP (0.79) | CREBBPLPAR2LPAR1PARP1PARP10 | |
| SCHEMBL15798246 | 1.00 | CREBBP (0.79) | CREBBPLPAR2LPAR1PARP1PARP10 | |
| SCHEMBL17395887 | 0.89 | CREBBP (1.00) | CREBBPLPAR2LPAR1PARP1PARP10 | |
| SCHEMBL17395885 | 0.89 | CREBBP (1.00) | CREBBPLPAR2LPAR1PARP1PARP10 | |
| SCHEMBL441804 | 0.88 | LPAR2 (1.00) | CREBBPLPAR2LPAR1PARP1PARP10 | |
| SCHEMBL1552033 | 0.88 | LPAR2 (1.00) | CREBBPLPAR2LPAR1PARP1PARP10 | |
| SCHEMBL441805 | 0.88 | LPAR2 (1.00) | CREBBPLPAR2LPAR1PARP1PARP10 | |
| Iodide SCHEMBL1552156 | 0.86 | LPAR2 (0.96) | CREBBPLPAR2LPAR1PARP1PARP10 | |
| SCHEMBL22272087 | 0.85 | CREBBP (0.63) | CREBBPLPAR2LPAR1PARP1PARP10 | |
| SCHEMBL11011737 | 0.84 | CREBBP (0.81) | CREBBPLPAR2LPAR1PARP1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0403240-B1 | Preparation process of N-substituted maleimides | MITSUI TOATSU CHEMICALS (JP) | 1994-08-24 | — | — | EP | claimed |
| EP-0372922-B1 | Preparation process of N-substituted maleimides | MITSUI TOATSU CHEMICALS (JP) | 1994-03-09 | — | — | EP | claimed |
| US-5175309-A | Forming an imide by heat catalytic dehydration | MITSUI TOATSU CHEMICALS INC. (JP) | 1992-12-29 | — | — | US | claimed |
| US-5068357-A | Heat dehydration of an N-substituted maleamic acid with a solvent, distillation after imidation, in the presence of a tin catalyst | MITSUI TOATSU CHEMICALS, INC. (JP) | 1991-11-26 | — | — | US | claimed |
| EP-0403240-A1 | Preparation process of N-substituted maleimides | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-12-19 | — | — | EP | claimed |
| EP-0372922-A2 | Preparation process of N-substituted maleimides | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-06-13 | — | — | EP | claimed |
| EP-2931280-B1 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS INC (US) | 2018-02-14 | — | — | EP | disclosed |
| US-9340532-B2 | Methods and compositions for inhibiting CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150307482-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2015-10-29 | — | — | US | disclosed |
| EP-2931280-A2 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | Phusis Therapeutics Inc. (US) | 2015-10-21 | — | — | EP | disclosed |
| WO-2014093988-A2 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| EP-0403240-B1 | Preparation process of N-substituted maleimides | MITSUI TOATSU CHEMICALS (JP) | 1994-08-24 | — | — | EP | disclosed |
| EP-0372922-B1 | Preparation process of N-substituted maleimides | MITSUI TOATSU CHEMICALS (JP) | 1994-03-09 | — | — | EP | disclosed |
| US-5175309-A | Forming an imide by heat catalytic dehydration | MITSUI TOATSU CHEMICALS INC. (JP) | 1992-12-29 | — | — | US | disclosed |
| US-5068357-A | Heat dehydration of an N-substituted maleamic acid with a solvent, distillation after imidation, in the presence of a tin catalyst | MITSUI TOATSU CHEMICALS, INC. (JP) | 1991-11-26 | — | — | US | disclosed |
| EP-0403240-A1 | Preparation process of N-substituted maleimides | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-12-19 | — | — | EP | disclosed |
| EP-0372922-A2 | Preparation process of N-substituted maleimides | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307482-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | CNKSR1, CAMKK1, CAMKK2 | CREBBP 510/4885LPAR2 834/4885LPAR1 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.